Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.

Hayato, Seiichi; Takenaka, Osamu; Sreerama Reddy, Sree Harsha; Landry, Ishani; Reyderman, Larisa; Koyama, Akihiko; Swanson, Chad; Yasuda, Sanae; Hussein, Ziad

Hayato, Seiichi; Takenaka, Osamu; Sreerama Reddy, Sree Harsha; Landry, Ishani; Reyderman, Larisa; Koyama, Akihiko; Swanson, Chad; Yasuda, Sanae; Hussein, Ziad.

Affiliation

Hayato S; Eisai Co., Ltd., Tokyo, Japan.
Takenaka O; Eisai Co., Ltd., Tokyo, Japan.
Sreerama Reddy SH; Eisai Inc., Nutley, New Jersey, USA.
Landry I; Eisai Inc., Nutley, New Jersey, USA.
Reyderman L; Eisai Inc., Nutley, New Jersey, USA.
Koyama A; Eisai Inc., Nutley, New Jersey, USA.
Swanson C; Eisai Inc., Nutley, New Jersey, USA.
Yasuda S; Eisai Inc., Nutley, New Jersey, USA.
Hussein Z; Eisai Ltd., Hatfield, UK.

CPT Pharmacometrics Syst Pharmacol ; 11(12): 1578-1591, 2022 12.

Article in En | MEDLINE | ID: mdl-36165093

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Amyloid beta-Peptides / Alzheimer Disease Limits: Humans Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2022 Document type: Article Affiliation country: Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google